Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Spyre Therapeutics, Inc. is a clinical-stage biotech focused on developing next-generation antibody therapies for inflammatory bowel disease (IBD) and immune-mediated diseases. Its pipeline includes engineered monoclonal antibodies targeting α4β7, TL1A, and IL-23, designed for improved efficacy, safety, and dosing convenience. The company emphasizes combination therapies and expansion into indications like rheumatoid arthritis, leveraging innovative antibody engineering and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.